MétaCan
Menu
← Back to cohort
Record W7117325961 · doi:10.1002/alz70858_107125

Comprehensive Individualized Person‐Centered Management Program Reduces Psychotropic Medication Costs and the Behavioral and Psychological Symptoms of Dementia in Advanced Alzheimer's Persons in a 28‐Week Randomized Controlled Trial

2025· article· en· W7117325961 on OpenAlexaff
Sunnie Kenowsky, Yongzhao Shao, Sloane Heller, James Golomb, Qiao Zhang, Gaurav Vedvyas, Gianna Dafflisio, Karyn Marsh, Martin Sadowski, Thomas Wisniewski, Arjun V. Masurkar, ‌Barry Reisberg

Bibliographic record

VenueAlzheimer s & Dementia · 2025
Typearticle
Languageen
FieldMedicine
TopicDementia and Cognitive Impairment Research
Canadian institutionsMcGill University Health Centre
Fundersnot available
KeywordsDementiaRandomized controlled trialPsychotropic medicationMedication adherenceClinical trialSchizophrenia (object-oriented programming)

Abstract

fetched live from OpenAlex

BACKGROUND: Behavioral and psychological symptoms of dementia (BPSD) occur frequently and cause suffering, burden, and institutionalization in Alzheimer's disease affected persons. Medications prescribed to treat BPSD are expensive and often are not highly effective. Brexpiprazole recently approved to treat Alzheimer's agitation carries a retail drug price of $79.50/pill. Acetylcholinesterase inhibitors (ACHI) have been found to ameliorate BPSD in Alzheimer's persons in some studies. However, they are not commonly prescribed for BPSD by community physicians. We published results of a 28-week, clinician-blind, randomized, controlled trial of our comprehensive, individualized person-centered management (CI-PCM) program in moderate-to-severe, community-residing Alzheimer's persons receiving memantine (doi:10.1159/000455397). We examined BPSD using the Behavioral Pathology in Alzheimer's Disease Frequency Weighted Severity Scale, which showed significantly decreased BPSD in the CI-PCM group at 28-weeks (p <0.05). Additionally, the total amount of psychotropic medication prescribed to treat BPSD was lower in CI-PCM subjects at 28-weeks in comparison to baseline (p <0.0001, https://doi.org/10.1002/alz.056048). Herein, we examine if CI-PCM subjects in our 2017 trial benefited from psychotropic medication cost savings and whether differential ACHI usage accounted for improvements in BPSD in the CI-PCM group. METHODS: Medication usage was captured at each study visit. Blinded investigators reviewed subject charts (N = 20), for total psychotropic drug usage and total psychotropic medication prescribed to treat BPSD. Retail drug pricing of each prescription was obtained from the NYU outpatient pharmacy to standardize costs. Total cost of psychotropic medication prescribed to treat BPSD was calculated for each individual and study group at baseline and weeks 4,12, and 28. Differences between groups were compared using the Wilcoxon Sum Rank test. RESULTS: There were no statistically significant differences between groups in ACHI used or not (p = 0.401), number of days on and days off ACHI (p = 0.58) or in costs of psychotropic medication taken. CI-PCM subjects paid $8,804.69 and Comparator subjects paid $24,901 from baseline to week 28 to treat BPSD. CONCLUSIONS: CI-PCM subjects saved an average of $1,609.63 and experienced improvements in BPSD whereas comparators spent 2.8 times more and had worsening BPSD. ACHI treatment did not differ significantly between the two groups or account for the improvement in CI-PCM group BPSD.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.005
Threshold uncertainty score0.017

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.002
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0020.002
Bibliometrics0.0000.000
Science and technology studies0.0010.001
Scholarly communication0.0010.001
Open science0.0010.000
Research integrity0.0020.002
Insufficient payload (model declined to judge)0.0050.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.049
GPT teacher head0.381
Teacher spread0.331 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueAlzheimer s & Dementia→Same topicDementia and Cognitive Impairment Research→French-language works237,207→